Identifying and Characterizing a Functional HIV-1 Reverse Transcriptase-binding Site on Integrase

被引:54
|
作者
Wilkinson, Thomas A. [1 ]
Januszyk, Kurt [2 ]
Phillips, Martin L. [2 ]
Tekeste, Shewit S. [1 ]
Zhang, Min [1 ]
Miller, Jennifer T. [3 ]
Le Grice, Stuart F. J. [3 ]
Clubb, Robert T. [2 ]
Chow, Samson A. [1 ]
机构
[1] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA
[3] NCI, HIV Drug Resistance Program, NIH, Frederick, MD 21702 USA
基金
美国国家卫生研究院;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL NUCLEIC-ACIDS; CRYSTAL-STRUCTURE; PREINTEGRATION COMPLEXES; ANGSTROM RESOLUTION; GENETIC-ANALYSIS; CATALYTIC CORE; DNA; DOMAIN; PROTEIN;
D O I
10.1074/jbc.M806241200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Integrase (IN) from human immunodeficiency virus, type 1 (HIV-1) exerts pleiotropic effects in the viral replication cycle. Besides integration, IN mutations can impact nuclear import, viral maturation, and reverse transcription. IN and reverse transcriptase (RT) interact in vitro, and the IN C-terminal domain (CTD) is both necessary and sufficient for binding RT. We used nuclear magnetic resonance spectroscopy to identify a putative RT-binding surface on the IN CTD, and surface plasmon resonance to obtain kinetic parameters and the binding affinity for the IN-RT interaction. An IN K258A substitution that disrupts reverse transcription in infected cells is located at the putative RT-binding surface, and we found that this substitution substantially weakens IN CTD-RT interactions. We also identified two additional IN amino acid substitutions located at the putative RT-binding surface (W243E and V250E) that significantly impair viral replication in tissue culture. These results strengthen the notion that IN-RT interactions are biologically relevant during HIV-1 replication and also provide insights into this interaction at the molecular level.
引用
收藏
页码:7931 / 7939
页数:9
相关论文
共 50 条
  • [31] Cytotoxic T-cell responses to HIV-1 reverse transcriptase, integrase and protease
    Haas, G
    Samri, A
    Gomard, E
    Hosmalin, A
    Duntze, J
    Bouley, EM
    Ihlenfeldt, HG
    Katlama, C
    Autran, E
    AIDS, 1998, 12 (12) : 1427 - 1436
  • [32] Low levels of reverse transcriptase associated with one integrase defective mutant of HIV-1
    Cara, A
    Cereseto, A
    Fiorentini, S
    Gusella, L
    Reitz, MS
    FUNDAMENTAL AND CLINICAL IMMUNOLOGY, 1996, 4 (02): : 61 - 66
  • [33] Evolution of HIV-1 reverse transcriptase and integrase dual inhibitors: Recent advances and developments
    Gill, Muhammad Shoaib Ali
    Hassan, Sharifah Syed
    Ahemad, Nafees
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 179 : 423 - 448
  • [34] Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors
    Latham, Catherine F.
    La, Jennifer
    Tinetti, Ricky N.
    Chalmers, David K.
    Tachedjian, Gilda
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (10) : 1135 - 1153
  • [35] Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
    Singh, Kamal
    Sarafianos, Stefan G.
    Sonnerborg, Anders
    PHARMACEUTICALS, 2019, 12 (02)
  • [36] HIV-1 reverse transcriptase inhibitors
    El Safadi, Yazan
    Vivet-Boudou, Valerie
    Marquet, Roland
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2007, 75 (04) : 723 - 737
  • [37] ACTIVE-SITE LABELING OF HIV-1 REVERSE-TRANSCRIPTASE
    SHENG, NJ
    DENNIS, D
    BIOCHEMISTRY, 1993, 32 (18) : 4938 - 4942
  • [38] HIV-1 reverse transcriptase inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1996, 1 (03) : 122 - 122
  • [39] HIV-1 reverse transcriptase inhibitors
    Yazan El Safadi
    Valérie Vivet-Boudou
    Roland Marquet
    Applied Microbiology and Biotechnology, 2007, 75 : 723 - 737
  • [40] Flavanone and flavonol glycosides from the leaves of Thevetia peruviana and their HIV-1 reverse transcriptase and HIV-1 integrase inhibitory activities
    Tewtrakul, S
    Nakamura, N
    Hattori, M
    Fujiwara, T
    Supavita, T
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2002, 50 (05) : 630 - 635